IE911707A1 - Use of a¹1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-¹tetra-hydropyridine for the manufacture of a medicament¹for the treatment of cerebral and neuronal diseases - Google Patents

Use of a¹1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-¹tetra-hydropyridine for the manufacture of a medicament¹for the treatment of cerebral and neuronal diseases

Info

Publication number
IE911707A1
IE911707A1 IE170791A IE170791A IE911707A1 IE 911707 A1 IE911707 A1 IE 911707A1 IE 170791 A IE170791 A IE 170791A IE 170791 A IE170791 A IE 170791A IE 911707 A1 IE911707 A1 IE 911707A1
Authority
IE
Ireland
Prior art keywords
compound
neuronal
treatment
formula
pharmaceutically acceptable
Prior art date
Application number
IE170791A
Other languages
English (en)
Other versions
IE83649B1 (en
Inventor
Fournier Jacqueline
Guzzi Umberto
Xavier Coude Francois
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of IE83649B1 publication Critical patent/IE83649B1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IE911707A1 publication Critical patent/IE911707A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IE170791A 1990-05-22 1991-05-20 Use of a¹1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-¹tetra-hydropyridine for the manufacture of a medicament¹for the treatment of cerebral and neuronal diseases IE911707A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRFRANCE22/05/19909006399
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (2)

Publication Number Publication Date
IE83649B1 IE83649B1 (en)
IE911707A1 true IE911707A1 (en) 1991-12-04

Family

ID=9396855

Family Applications (1)

Application Number Title Priority Date Filing Date
IE170791A IE911707A1 (en) 1990-05-22 1991-05-20 Use of a¹1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-¹tetra-hydropyridine for the manufacture of a medicament¹for the treatment of cerebral and neuronal diseases

Country Status (16)

Country Link
US (3) US5229389A (OSRAM)
EP (2) EP0655247B1 (OSRAM)
JP (2) JP2618115B2 (OSRAM)
KR (1) KR0181330B1 (OSRAM)
AT (2) ATE132369T1 (OSRAM)
BR (1) BR9105015A (OSRAM)
CA (2) CA2042974C (OSRAM)
CY (1) CY2283B1 (OSRAM)
DE (2) DE69132797T2 (OSRAM)
DK (2) DK0458696T3 (OSRAM)
FR (1) FR2662355B1 (OSRAM)
HU (1) HU208922B (OSRAM)
IE (1) IE911707A1 (OSRAM)
IL (3) IL112167A (OSRAM)
TW (1) TW216771B (OSRAM)
ZA (1) ZA913865B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2672213B1 (fr) 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
US6043251A (en) * 1995-10-26 2000-03-28 Sanofi Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyr idine for preparing drugs for treating amyotrophic lateral sclerosis
EP0890105B1 (en) * 1996-03-29 2006-11-22 The Trustees Of Boston University Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
WO1998033502A1 (fr) * 1997-02-03 1998-08-06 Sanofi-Synthelabo Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
DE69115989T2 (de) 1996-08-22
US5229389A (en) 1993-07-20
EP0458696B1 (fr) 1996-01-03
DE69115989D1 (de) 1996-02-15
DK0458696T3 (da) 1996-05-20
BR9105015A (pt) 1993-05-25
HUT59824A (en) 1992-07-28
US5468753A (en) 1995-11-21
CY2283B1 (en) 2003-07-04
EP0655247A1 (fr) 1995-05-31
IL98175A (en) 1996-01-19
CA2365832A1 (en) 1991-11-23
JPH09132535A (ja) 1997-05-20
JPH04226917A (ja) 1992-08-17
AU636488B2 (en) 1993-04-29
KR0181330B1 (ko) 1999-03-20
CA2365832C (en) 2007-08-07
IL112167A (en) 1996-01-31
HK1001471A1 (en) 1998-06-19
JP2954029B2 (ja) 1999-09-27
IE20011078A1 (en) 2002-03-20
HU911729D0 (en) 1991-12-30
EP0655247B1 (fr) 2001-10-31
EP0458696A2 (fr) 1991-11-27
JP2618115B2 (ja) 1997-06-11
HU208922B (en) 1994-02-28
IL98175A0 (en) 1992-06-21
EP0458696A3 (en) 1992-03-18
ATE207747T1 (de) 2001-11-15
FR2662355B1 (fr) 1994-11-10
DK0655247T3 (da) 2002-02-18
ZA913865B (en) 1992-02-26
KR910019617A (ko) 1991-12-19
DE69132797T2 (de) 2002-05-29
CA2042974C (en) 2002-09-17
ATE132369T1 (de) 1996-01-15
IL112167A0 (en) 1995-03-15
US5270320A (en) 1993-12-14
CA2042974A1 (en) 1991-11-22
AU7713391A (en) 1991-11-28
TW216771B (OSRAM) 1993-12-01
DE69132797D1 (de) 2001-12-06
FR2662355A1 (fr) 1991-11-29

Similar Documents

Publication Publication Date Title
US5229389A (en) Method for evaluating neuronal activity of a drug
IE83649B1 (en) Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetra-hydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases
Levin et al. Nicotinic acetylcholine involvement in cognitive function in animals
Junker et al. Stimulation of β-adrenoceptors activates astrocytes and provides neuroprotection
Maurice et al. Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction
Akaneya et al. Involvement of free radicals in MPP+ neurotoxicity against rat dopaminergic neurons in culture
SK15702000A3 (sk) Použitie
CN111655669A (zh) 治疗包括运动神经元疾病的神经紊乱的组合物和方法
Hulley et al. Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo
Jonnala et al. Relative levels of cytoprotection produced by analogs of choline and the role of α7‐nicotinic acetylcholine receptors
Long et al. Regional differences in the response of serotonergic neurons in rat CNS to drugs
Bäckman et al. Effects of transferrin receptor antibody-NGF conjugate on young and aged septal transplants in oculo
Ferrari-Dileo et al. Glaucoma, Capillaries and Pericytes. 3. Peptide Hormone Binding and Influence on Pericytes: 3. Peptide Hormone Binding and Influence on Pericytes
Taslim et al. Role of mouse cerebellar nicotinic acetylcholine receptor (nAChR) α4β2-and α7 subtypes in the behavioral cross-tolerance between nicotine and ethanol-induced ataxia
Monti et al. Sleep and waking in 5, 7-DHT-lesioned or (−)-pindolol-pretreated rats after administration of buspirone, ipsapirone, or gepirone
Dick et al. Investigation of the interaction between nitric oxide and vasoactive intestinal polypeptide in the guinea‐pig gastric fundus
Reiser Nitric oxide formation caused by Ca2+ release from internal stores in neuronal cell line is enhanced by cyclic AMP
Maragos et al. Inhibition of nitric oxide synthase activity attenuates striatal malonate lesions in rats
Poli et al. Spontaneous recovery of MPTP-damaged catecholamine systems in goldfish brain areas
Perry Cholinergic component of cognitive impairment in dementia
Drugge et al. Trophic influence of sympathetic neurons on the cardiac alpha-adrenergic response requires close nerve-muscle association
HU211924A9 (hu) 1 -(2-NaftiI -étil)-4-(3-trifI uor-metil-fenil)-1,2,3,6-tetrahidropiridint tartalmazó, agyi és idegrendszeri megbetegedések kezelésére való gyógyszerkészítmények
Song Does levodopa affect endogenous and exogenous dopaminergic neuron survival?
WO2004065567A2 (en) Brain progenitor cell-based assay, and related methods and compositions
IE83650B1 (en) Use of vincristine for the evaluation of substances at the neuronal level

Legal Events

Date Code Title Description
MK9A Patent expired